Events
Multi Criteria Decision Analysis (MCDA) in healthcare: Current applications and ongoing challenges
SDP Free webinar
24 Aug, 2017 | 8:00 am PT / 11:00 am ET
Speaker: Kevin Marsh, Evidera
Moderator: Jon Mauer, Pfizer
Abstract:
Healthcare decision makers have recently show interest in the use of MCDA to support approval and reimbursement decisions. More conventionally used to support prioritization of investments, either within life sciences companies or healthcare providers, the application of MCDA to value individual technologies has raised a number of challenges. This webinar will provide a brief introduction to MCDA, and illustrate these recent trends in its application in healthcare and how these are seen as a way to overcome limitations in existing approaches, such as qualitative or semi-quantitative benefit-risk assessment, and cost-utility analysis. The majority of the webinar will focus on illustrating and identifying potential solutions to the challenges posed by these uses of MCDA, including: the need for non-additive aggregation functions in reimbursement decisions; eliciting weights from patients who might struggle with clinical data; incorporating cost and uncertainty into the analysis; the choice of weight elicitation technique; and regulators concerns about the validity of MCDA. The webinar will conclude with a summary of ongoing initiatives to address these challenges.
24 Aug, 2017 | 8:00 am PT / 11:00 am ET
Speaker: Kevin Marsh, Evidera
Moderator: Jon Mauer, Pfizer
Abstract:
Healthcare decision makers have recently show interest in the use of MCDA to support approval and reimbursement decisions. More conventionally used to support prioritization of investments, either within life sciences companies or healthcare providers, the application of MCDA to value individual technologies has raised a number of challenges. This webinar will provide a brief introduction to MCDA, and illustrate these recent trends in its application in healthcare and how these are seen as a way to overcome limitations in existing approaches, such as qualitative or semi-quantitative benefit-risk assessment, and cost-utility analysis. The majority of the webinar will focus on illustrating and identifying potential solutions to the challenges posed by these uses of MCDA, including: the need for non-additive aggregation functions in reimbursement decisions; eliciting weights from patients who might struggle with clinical data; incorporating cost and uncertainty into the analysis; the choice of weight elicitation technique; and regulators concerns about the validity of MCDA. The webinar will conclude with a summary of ongoing initiatives to address these challenges.
Add this event to your calendar
|
Location
GoToWebinar
|
|
Dates
Aug 24, 2017
08:00 AM - 09:00 AM |
|
Contact
Hilda Cherekdjian
|
|
Respondent Email
|
Speaker
Kevin Marsh, Eviderag
Kevin Marsh, PhD, is Executive Director at Evidera in London, UK. His research interests include the use of stated and revealed preference methods, decision modelling, and MCDA to support healthcare decisions. He co-Chaired the ISPOR Task Force on the Use of MCDA in Health Care Decision-Making. He is currently co-chairing an ISPOR working group on the use of preference data in European decision making, and is a co-convenor of the Campbell and Cochrane Economic Methods Group. Dr Marsh completed his PhD at the University of Bath, specialising in economic valuation techniques.
.
Moderator
Jon Mauer, Pfizer
Before learning decision analysis, Jon practiced pharmacy in the Indian Health Service (Navajo) and in Beth Israel Medical Center. He earned his MBA and joined Bristol-Myers Squibb’s Information Management staff in 1998 where he developed a strong interest in Decision Analysis (DA). In 1999, Jon embraced DA when the capability was piloted at Bristol-Myers Squibb. He joined the Decision Analysis & Portfolio Management department and helped develop and embed the capabilities over the next decade.
Jon joined Pfizer’s Portfolio and Decision Analysis staff in 2010 and led the decision-education program to integrate new colleagues following Pfizer’s acquisition of Wyeth. Later, Jon expanded the use of DA to support public policy and inform medical decision-making.
